Title:
アンドロゲン受容体拮抗薬として使用されるジアリールチオヒダントイン化合物
Document Type and Number:
Japanese Patent JP7285838
Kind Code:
B2
Abstract:
The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
Inventors:
Chun Li Shen
▲呉▼ 成▲徳▼
▲陳▼ ▲勝▼林
▲陳▼ 曙▲輝▼
▲張▼ 喜全
Tashin
▲呉▼ 成▲徳▼
▲陳▼ ▲勝▼林
▲陳▼ 曙▲輝▼
▲張▼ 喜全
Tashin
Application Number:
JP2020529797A
Publication Date:
June 02, 2023
Filing Date:
August 07, 2018
Export Citation:
Assignee:
Shodai Ten Haru
International Classes:
C07D403/04; A61K31/437; A61K31/517; A61K31/553; A61P5/26; A61P43/00; C07D403/14; C07D405/14; C07D413/04; C07D471/04; C07D519/00
Foreign References:
| CN104341396A | ||||
| CN106146474A | ||||
| CN103804358A |
Other References:
GUO, C. et al.,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists,Bioorganic & Medicinal Chemistry Letters,2012年,Vol.22,pp.2572-2578,DOI:10.1016/j.bmcl.2012.01.116
Attorney, Agent or Firm:
Yasuhiko Murayama
Shinya Mihiro
Tatsuhiko Abe
Shinya Mihiro
Tatsuhiko Abe
Previous Patent: Sulfasalazine salt, method of preparation and use
Next Patent: COMPOSITION FOR ORAL CAVITY APPLICATION
Next Patent: COMPOSITION FOR ORAL CAVITY APPLICATION